News | April 09, 2007

Bayer HealthCare Pharmaceuticals Officially Launched in U.S.

April 10, 2007 - Bayer HealthCare Pharmaceuticals Inc. announced its official U.S. launch. The new company incorporates the former Berlex Inc. into Bayer HealthCare Pharmaceuticals, as part of Bayer's acquisition of Schering AG, Germany, Berlex's former parent company.

Bayer HealthCare Pharmaceuticals Inc., headquartered in Wayne, NJ, is the U.S.-based pharmaceuticals unit of Bayer HealthCare. Bayer HealthCare's pharmaceutical business is dedicated to developing, manufacturing and marketing products that help improve human health, and globally ranks among the top 10 specialty pharmaceutical companies. The global pharmaceutical business employs more than 40,000 people, with approximately 5,500 employees in the U.S.

The company's global Oncology and Specialized Therapeutics business units, as well as certain U.S.-based global drug development groups and other business support functions, will be housed in its Montville, N.J. offices. The establishment of Bayer HealthCare Pharmaceuticals is expected to bring an estimated 300 new jobs to New Jersey.

The combined company has a robust research and development program with a strong product pipeline geared toward developing meaningful new therapeutic options to fulfill unmet medical needs. As a result of these two companies combining forces, research and development activities have been consolidated into three major sites (Berkeley, Calif., Berlin and Wuppertal, Germany). The Berkeley facility is an important R&D center for protein-based biologics and will house the company's global Hematology/Cardiology business.

Research in Diagnostic Imaging, Women's Healthcare and Oncology will be based in Berlin. Wuppertal will house the core of the company's Cardiology research. Both locations have significant capabilities and activities in target discovery, lead generation and optimization, drug metabolism and pharmacokinetics, toxicology and clinical pharmacology.

Bayer also will continue operations in Washington State to manufacture the company's white blood cell growth factor.

For more information, contact www.berlex.com.

Related Content

Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...
ASTRO 2019 to Feature Clinical Experience and Patient Outcomes With Viewray MRIdian
News | Image Guided Radiation Therapy (IGRT) | September 11, 2019
ViewRay Inc. announced that the company's MRIdian and MRIdian Linac magnetic resonance imaging (MRI)-guided radiation...
PTW to Feature New Dosimetry Technology at ASTRO 2019
News | Radiation Therapy | August 27, 2019
Radiation dosimetry company announced plans to exhibit its full range of radiation therapy dosimetry solutions for...
First Cancer Patient Treated With Accuray Radixact System With Synchrony Motion Tracking
News | Image Guided Radiation Therapy (IGRT) | August 21, 2019
Physicians at the Froedtert & the Medical College of Wisconsin (MCW) Clinical Cancer Center in Milwaukee have...
MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res